| Dr Kevin B Gebke, MD | |
|
1110 W Michigan St, Indianapolis, IN 46202-5209 | |
| (317) 278-0118 | |
| (317) 274-4444 |
| Full Name | Dr Kevin B Gebke |
|---|---|
| Gender | Male |
| Speciality | Family Medicine - Sports Medicine |
| Location | 1110 W Michigan St, Indianapolis, Indiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316903511 | NPI | - | NPPES |
| 200331600 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207QS0010X | Family Medicine - Sports Medicine | 01052849 (Indiana) | Primary |
| Entity Name | University Family Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043275787 PECOS PAC ID: 7911992797 Enrollment ID: O20040420000393 |
News Archive
A recent case report published on May 14, 2010 in World Journal of Gastroenterology describes the imaging features of a ruptured superior mesenteric artery aneurysm,which created a giant hematoma and mimicked a pancreatic mass, with mild dilatation of main pancreatic duct.
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer.
Cancer is incredibly complex, and each tumour is unique. This calls for a targeted approach. Researchers at KU Leuven's Department of Oncology, in Belgium, want to fight cancer by developing 'personalised' cancer therapies. To bolster their efforts, they have established the new Fund for Innovative Cancer Research.
Omeros Corporation today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system, has received orphan drug designation from the U.S. Food and Drug Administration for prevention of complement-mediated thrombotic microangiopathies.
Researchers at Uppsala University have cloned a T-cell receptor that binds to an antigen associated with prostate cancer and breast cancer. T cells that have been genetically equipped with this T-cell receptor have the ability to specifically kill prostate and breast cancer cells.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kevin B Gebke, MD 250 N Shadeland Ave, Indianapolis, IN 46219-4959 Ph: () - | Dr Kevin B Gebke, MD 1110 W Michigan St, Indianapolis, IN 46202-5209 Ph: (317) 278-0118 |
News Archive
A recent case report published on May 14, 2010 in World Journal of Gastroenterology describes the imaging features of a ruptured superior mesenteric artery aneurysm,which created a giant hematoma and mimicked a pancreatic mass, with mild dilatation of main pancreatic duct.
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer.
Cancer is incredibly complex, and each tumour is unique. This calls for a targeted approach. Researchers at KU Leuven's Department of Oncology, in Belgium, want to fight cancer by developing 'personalised' cancer therapies. To bolster their efforts, they have established the new Fund for Innovative Cancer Research.
Omeros Corporation today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system, has received orphan drug designation from the U.S. Food and Drug Administration for prevention of complement-mediated thrombotic microangiopathies.
Researchers at Uppsala University have cloned a T-cell receptor that binds to an antigen associated with prostate cancer and breast cancer. T cells that have been genetically equipped with this T-cell receptor have the ability to specifically kill prostate and breast cancer cells.
› Verified 9 days ago
Leigha Marie Murphy, NP Family Medicine Medicare: Medicare Enrolled Practice Location: 8904 Bash St Ste B, Indianapolis, IN 46256 Phone: 317-735-6001 Fax: 855-450-1177 | |
Donald H Lauer, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1250 E County Line Rd, Suite 9, Indianapolis, IN 46227 Phone: 317-881-9797 Fax: 317-881-4156 | |
Robert Kiess Newton, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9560 E 59th St, Indianapolis, IN 46216 Phone: 317-621-1700 Fax: 317-621-1711 | |
Dr. Bernard M Herbst, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 5839 E Washington St, Indianapolis, IN 46219 Phone: 317-353-9777 Fax: 317-357-6922 | |
Teresa Trierweiler, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4880 Century Plaza Rd, Suite 200, Indianapolis, IN 46254 Phone: 317-293-4113 Fax: 317-290-2542 | |
Dr. Phumeza Msikinya, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8920 Southpointe Dr Ste B, Indianapolis, IN 46227 Phone: 317-497-1900 | |
Ruben Hernan Hernandez Mondragon, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1040 Wishard Blvd, Indianapolis, IN 46202 Phone: 317-962-8893 Fax: 317-962-2990 |